Integrative/JJ
Analysis/NN
of/IN
Microarray/NN
Data/NNS
with/IN
Gene/NN
Ontology/NN
to/TO
Select/JJ
Perturbed/JJ
Molecular/JJ
Functions/NNS
using/VBG
Gene/NN
Ontology/NN
Functional/JJ
Code/NN
./.
====================
A/DT
systems/NNS
biology/NN
approach/NN
for/IN
the/DT
identification/NN
of/IN
perturbed/VBN
molecular/JJ
functions/NNS
is/VBZ
required/VBN
to/TO
understand/VB
the/DT
complex/NN
progressive/JJ
disease/NN
such/JJ
as/IN
breast/NN
cancer/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyze/VBP
the/DT
microarray/NN
data/NNS
with/IN
Gene/NN
Ontology/NN
terms/NNS
of/IN
molecular/JJ
functions/NNS
to/TO
select/VB
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
in/IN
breast/NN
cancer/NN
tissues/NNS
based/VBN
on/IN
the/DT
definition/NN
of/IN
Gene/NN
ontology/NN
Functional/JJ
Code/NN
./.
====================
The/DT
Gene/NN
Ontology/NN
is/VBZ
three/CD
structured/JJ
vocabularies/NNS
describing/VBG
genes/NNS
and/CC
its/PRP$
products/NNS
in/IN
terms/NNS
of/IN
their/PRP$
associated/VBN
biological/JJ
processes/NNS
,/,
cellular/JJ
components/NNS
and/CC
molecular/JJ
functions/NNS
./.
====================
The/DT
Gene/NN
Ontology/NN
is/VBZ
hierarchically/RB
classified/VBN
as/IN
a/DT
directed/JJ
acyclic/JJ
graph/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
difficult/JJ
to/TO
visualize/VB
Gene/NN
Ontology/NN
as/IN
a/DT
directed/JJ
tree/CD
since/IN
a/DT
Gene/NN
Ontology/NN
term/NN
may/MD
have/VB
more/RBR
than/IN
one/CD
parent/JJ
by/IN
providing/VBG
multiple/JJ
paths/NNS
from/IN
the/DT
root/NN
./.
====================
Therefore/RB
,/,
we/PRP
applied/VBD
the/DT
definition/NN
of/IN
Gene/NN
Ontology/NN
codes/VBZ
by/IN
defining/VBG
one/CD
or/CC
more/RBR
GO/NN
code/VBP
(/(
s/NNS
)/)
to/TO
each/DT
GO/NN
term/NN
to/TO
visualize/VB
the/DT
hierarchical/JJ
classification/NN
of/IN
GO/NN
terms/NNS
as/IN
a/DT
network/NN
./.
====================
The/DT
selected/VBN
molecular/JJ
functions/NNS
could/MD
be/VB
considered/VBN
as/IN
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
that/DT
putatively/RB
contributes/VBZ
to/TO
the/DT
progression/NN
of/IN
disease/NN
./.
====================
We/PRP
evaluated/VBD
the/DT
method/NN
by/IN
analyzing/VBG
microarray/NN
dataset/NN
of/IN
breast/NN
cancer/NN
tissues/NNS
;/:
i./FW
e./FW
,/,
normal/JJ
and/CC
invasive/JJ
breast/NN
cancer/NN
tissues/NNS
./.
====================
Based/VBN
on/IN
the/DT
integration/NN
approach/NN
,/,
we/PRP
selected/VBD
several/JJ
interesting/JJ
perturbed/VBN
molecular/JJ
functions/NNS
that/IN
are/VBP
implicated/VBN
in/IN
the/DT
progression/NN
of/IN
breast/NN
cancers/NNS
./.
====================
Moreover/RB
,/,
these/DT
selected/VBN
molecular/JJ
functions/NNS
include/VBP
several/JJ
known/JJ
breast/NN
cancer-related/JJ
genes/NNS
./.
====================
It/PRP
is/VBZ
concluded/VBN
from/IN
this/DT
study/NN
that/IN
the/DT
present/JJ
strategy/NN
is/VBZ
capable/JJ
of/IN
selecting/VBG
perturbed/VBN
molecular/JJ
functions/NNS
that/IN
putatively/RB
play/VBP
roles/NNS
in/IN
the/DT
progression/NN
of/IN
diseases/NNS
and/CC
provides/VBZ
an/DT
improved/JJ
interpretability/NN
of/IN
GO/NN
terms/NNS
based/VBN
on/IN
the/DT
definition/NN
of/IN
Gene/NN
Ontology/NN
codes/VBZ
./.
====================
A/DT
major/JJ
challenge/NN
in/IN
molecular/JJ
biology/NN
is/VBZ
the/DT
identification/NN
of/IN
genes/NNS
or/CC
molecular/JJ
functions/NNS
involved/VBN
in/IN
diseases/NNS
and/CC
other/JJ
biological/JJ
process/NN
./.
====================
Over/RB
the/DT
past/NN
decades/NNS
,/,
DNA/NN
microarrays/NNS
have/VBP
been/VBN
widely/RB
used/VBN
for/IN
this/DT
problem/NN
due/JJ
to/TO
their/PRP$
ability/NN
of/IN
parallel/JJ
monitoring/VBG
of/IN
the/DT
genomewide/NN
transcriptional/JJ
profiling/NN
./.
====================
The/DT
conventional/JJ
analysis/NN
of/IN
microarray/NN
data/NNS
starts/VBZ
with/IN
normalization/NN
,/,
followed/VBN
by/IN
the/DT
test/NN
statistics/NNS
to/TO
compare/VB
expression/NN
levels/NNS
in/IN
different/JJ
phenotypes/NNS
for/IN
each/DT
gene/NN
,/,
yielding/VBG
thousands/NNS
of/IN
differentially/RB
expressed/VBN
genes/NNS
(/(
Dhanasekaran/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
However/RB
,/,
this/DT
strategy/NN
is/VBZ
limited/JJ
due/JJ
to/TO
the/DT
fact/NN
that/IN
differentially/RB
expressed/VBN
genes/NNS
can/MD
be/VB
analyzed/VBN
oneatatime/CD
./.
====================
In/IN
addition/NN
,/,
most/JJS
genes/NNS
are/VBP
known/VBN
to/TO
function/VB
in/IN
concert/NN
rather/RB
than/IN
alone/RB
,/,
and/CC
their/PRP$
products/NNS
interact/VBP
with/IN
each/DT
other/JJ
and/CC
with/IN
DNA/NN
by/IN
forming/VBG
dynamic/JJ
topological/JJ
interactomes/VBZ
./.
====================
Therefore/RB
,/,
a/DT
systems/NNS
biology/NN
approach/NN
that/DT
can/MD
identify/VB
perturbed/VBN
molecular/JJ
functions/NNS
with/IN
differentially/RB
expressed/VBN
genes/NNS
would/MD
accelerate/VB
the/DT
understanding/NN
the/DT
basic/JJ
molecular/JJ
mechanism/NN
of/IN
certain/JJ
phenotypes/NNS
or/CC
diseases/NNS
./.
====================
The/DT
Gene/NN
Ontology/NN
(/(
The/DT
Gene/NN
Ontology/NN
Consortium/NN
,/,
2000/CD
)/)
is/VBZ
a/DT
database/NN
of/IN
structured/JJ
controlled/VBN
ontology/RB
that/DT
describe/VBP
gene/NN
product/NN
in/IN
terms/NNS
of/IN
their/PRP$
biological/JJ
processes/NNS
,/,
cellular/JJ
components/NNS
,/,
and/CC
molecular/JJ
functions/NNS
./.
====================
GO/NN
is/VBZ
a/DT
hierarchically/RB
structure/NN
forming/VBG
an/DT
acyclic/JJ
digraph/NN
with/IN
topdown/JJ
directions/NNS
,/,
which/WDT
provides/VBZ
an/DT
efficient/JJ
navigation/NN
for/IN
the/DT
structure/NN
of/IN
the/DT
ontology/NN
./.
====================
However/RB
,/,
the/DT
same/JJ
GO/NN
term/NN
may/MD
occur/VB
in/IN
different/JJ
lines/NNS
of/IN
ontology/NN
structure/NN
./.
====================
It/PRP
means/NNS
that/DT
GO/NN
may/MD
not/RB
be/VB
represented/VBN
as/IN
directed/VBN
tree/CD
since/IN
a/DT
GO/NN
term/NN
may/MD
have/VB
more/RBR
than/IN
one/CD
parent/JJ
providing/VBG
multiple/JJ
paths/NNS
from/IN
the/DT
root/NN
./.
====================
To/TO
construct/VB
an/DT
ordered/VBN
GO/NN
tree/CD
for/IN
the/DT
purpose/NN
of/IN
global/JJ
visualization/NN
,/,
GO/NN
terms/NNS
need/VBD
to/TO
be/VB
distinguished/VBN
from/IN
one/CD
another/DT
if/IN
they/PRP
are/VBP
occurred/VBN
in/IN
different/JJ
locations/NNS
on/IN
the/DT
hierarchical/JJ
classification/NN
of/IN
gene/NN
ontology/NN
./.
====================
Based/VBN
on/IN
the/DT
biological/JJ
point/NN
of/IN
view/NN
,/,
Lee/NNP
et/FW
al/JJ
./.
====================
(/(
2004/CD
)/)
justified/VBN
that/DT
what/WP
is/VBZ
more/RBR
important/JJ
is/VBZ
not/RB
a/DT
GO/NN
term/NN
itself/PRP
,/,
but/CC
which/WDT
path/NN
the/DT
GO/NN
terms/NNS
takes/VBZ
from/IN
the/DT
root/NN
in/IN
the/DT
gene/NN
ontology/NN
./.
====================
It/PRP
means/NNS
that/DT
each/DT
location/NN
of/IN
a/DT
GO/NN
term/NN
could/MD
be/VB
considered/VBN
distinct/JJ
if/IN
a/DT
distinct/JJ
path/NN
leads/VBZ
to/TO
it/PRP
from/IN
the/DT
root/NN
of/IN
gene/NN
ontology/NN
./.
====================
Therefore/RB
,/,
we/PRP
de/FW
fined/JJ
Gene/NN
ontology/NN
Functional/JJ
Code/NN
(/(
GFC/NN
)/)
to/TO
each/DT
GO/NN
term/NN
based/VBN
on/IN
the/DT
definition/NN
of/IN
GO/NN
codes/VBZ
by/IN
Lee/NNP
et/FW
al/JJ
./.
====================
(/(
2004/CD
)/)
./.
====================
Note/RB
that/DT
a/DT
unique/JJ
GO/NN
code/VBP
is/VBZ
assigned/VBN
to/TO
a/DT
GO/NN
term/NN
in/IN
each/DT
location/NN
of/IN
the/DT
classification/NN
of/IN
gene/NN
ontology/NN
./.
====================
It/PRP
therefore/RB
means/NNS
that/DT
the/DT
visualization/NN
of/IN
gene/NN
ontology/NN
based/VBN
on/IN
GO/NN
codes/VBZ
will/MD
provide/VB
more/RBR
interpretability/NN
of/IN
gene/NN
ontology/NN
than/IN
the/DT
one/CD
based/VBN
on/IN
GO/NN
terms/NNS
./.
====================
Many/JJ
progressive/JJ
diseases/NNS
such/JJ
as/IN
cancer/NN
are/VBP
caused/VBN
by/IN
combinatorial/JJ
effect/NN
of/IN
multiple/JJ
genes/NNS
rather/RB
than/IN
a/DT
single/JJ
gene/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
integrated/VBD
the/DT
microarray/NN
data/NNS
with/IN
GO/NN
terms/NNS
to/TO
find/VB
the/DT
perturbed/JJ
molecular/JJ
functions/NNS
in/IN
breast/NN
cancer/NN
tissues/NNS
using/VBG
GO/NN
codes/VBZ
in/IN
molecular/JJ
function/NN
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
identify/VBP
several/JJ
perturbed/JJ
molecular/JJ
functions/NNS
that/IN
are/VBP
implicated/VBN
to/TO
play/VB
roles/NNS
in/IN
the/DT
progression/NN
of/IN
breast/NN
cancer/NN
./.
====================
The/DT
hierarchical/JJ
classification/NN
of/IN
gene/NN
ontology/NN
is/VBZ
basically/RB
represented/VBN
as/IN
a/DT
directed/JJ
acyclic/JJ
graph/NN
(/(
DAG/NN
)/)
with/IN
three/CD
categories/NNS
,/,
namely/RB
molecular/JJ
function/NN
,/,
biological/JJ
process/NN
and/CC
cellular/JJ
component/NN
(/(
Ashburner/NN
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
Based/VBN
on/IN
this/DT
hierarchical/JJ
classification/NN
,/,
GO/NN
terms/NNS
can/MD
be/VB
represented/VBN
as/IN
node/NN
by/IN
an/DT
acyclic/JJ
digraph/NN
./.
====================
However/RB
,/,
GO/NN
DAG/NN
is/VBZ
difficult/JJ
to/TO
be/VB
visualized/VBN
as/IN
a/DT
directed/JJ
tree/CD
since/IN
a/DT
GO/NN
term/NN
may/MD
have/VB
more/RBR
than/IN
one/CD
parent/JJ
by/IN
providing/VBG
multiple/JJ
paths/NNS
from/IN
the/DT
root/NN
./.
====================
Thus/RB
,/,
we/PRP
have/VBP
adopted/VBN
the/DT
definition/NN
of/IN
GO/NN
code/VBP
(/(
Lee/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Fig/NN
./.
====================
1/CD
)/)
,/,
in/IN
which/WDT
GO/NN
terms/NNS
can/MD
be/VB
efficiently/RB
handled/VBN
in/IN
a/DT
tree/JJ
structure/NN
by/IN
defining/VBG
one/CD
or/CC
more/RBR
GO/NN
code/VBP
(/(
s/NNS
)/)
to/TO
each/DT
GO/NN
term/NN
,/,
to/TO
visualize/VB
the/DT
hierarchical/JJ
classification/NN
of/IN
GO/NN
terms/NNS
as/IN
a/DT
network/NN
./.
====================
That/DT
is/VBZ
,/,
a/DT
GO/NN
code/VBP
is/VBZ
assigned/VBN
to/TO
a/DT
GO/NN
term/NN
in/IN
each/DT
location/NN
of/IN
the/DT
classification/NN
of/IN
gene/NN
ontology/NN
./.
====================
A/DT
GO/NN
term/NN
is/VBZ
transformed/VBN
into/IN
a/DT
GO/NN
code/VBP
α1α2α3…αH/JJ
using/VBG
the/DT
unique/JJ
path/NN
from/IN
the/DT
root/NN
of/IN
the/DT
classification/NN
of/IN
GO/NN
to/TO
each/DT
GO/NN
term/NN
,/,
in/IN
which/WDT
H/NN
is/VBZ
the/DT
length/NN
of/IN
a/DT
longest/RBR
path/NN
from/IN
the/DT
root/NN
to/TO
each/DT
GO/NN
term/NN
in/IN
the/DT
classification/NN
of/IN
GO/NN
./.
====================
The/DT
GO/NN
codes/VBZ
can/MD
be/VB
represented/VBN
as/IN
nodes/NNS
in/IN
the/DT
ordered/VBN
tree/CD
of/IN
GO/NN
category/NN
./.
====================
Each/DT
node/NN
is/VBZ
located/JJ
on/IN
the/DT
level/NN
N/NN
of/IN
GO/NN
tree/CD
for/IN
N=1,2/NN
,/,
…H/NN
./.
====================
See/JJ
Lee/NNP
et/FW
al/JJ
./.
====================
’/CD
s/NNS
(/(
2004/CD
)/)
study/NN
for/IN
more/RBR
detail/NN
of/IN
GO/NN
code/VBP
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
focused/VBN
on/IN
the/DT
GO/NN
code/VBP
for/IN
the/DT
GO/NN
term/NN
of/IN
molecular/JJ
function/NN
,/,
which/WDT
is/VBZ
defined/VBN
as/IN
Gene/NN
ontology/NN
Functional/JJ
Code/NN
(/(
GFC/NN
)/)
./.
====================
Note/RB
that/DT
for/IN
the/DT
probe/NN
set/NN
of/IN
Affymetrix/JJ
GeneChip/NN
Human/JJ
Genome/NN
U133/NN
Plus/JJ
2.0/CD
Array/NN
chip/NN
,/,
the/DT
distribution/NN
of/IN
GFC/NN
classes/NNS
and/CC
average/NN
number/NN
of/IN
entries/VBZ
per/IN
each/DT
GFC/NN
class/NN
corresponding/VBG
to/TO
the/DT
level/NN
of/IN
GFC/NN
is/VBZ
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
To/TO
visualize/VB
the/DT
perturbed/JJ
molecular/JJ
functions/NNS
in/IN
breast/NN
cancer/NN
tissues/NNS
using/VBG
GFC/NN
,/,
we/PRP
analyzed/VBD
the/DT
microarray/NN
dataset/NN
from/IN
Turashvilli/NN
et/FW
al/JJ
./.
====================
(/(
2007/CD
)/)
,/,
which/WDT
consists/VBZ
of/IN
2/CD
types/NNS
of/IN
breast/NN
cancer/NN
tissues/NNS
;/:
i./FW
e./FW
,/,
invasive/JJ
lobular/JJ
and/CC
ductal/JJ
carcinomas/NNS
./.
====================
This/DT
dataset/NN
includes/VBZ
a/DT
total/JJ
of/IN
30/CD
samples/NNS
that/DT
consist/VBP
of/IN
10/CD
samples/NNS
from/IN
normal/JJ
ductal/JJ
cells/NNS
,/,
10/CD
samples/NNS
from/IN
normal/JJ
lobular/JJ
cells/NNS
,/,
5/CD
samples/NNS
from/IN
invasive/JJ
ductal/JJ
carcinoma/NN
cells/NNS
,/,
and/CC
5/CD
samples/NNS
from/IN
invasive/JJ
lobular/JJ
carcinoma/NN
cells/NNS
,/,
which/WDT
were/VBD
microdissected/VBN
from/IN
cryosections/NNS
of/IN
10/CD
mastectomy/NN
specimens/NNS
from/IN
postmenopausal/JJ
patients/NNS
./.
====================
Before/IN
selecting/VBG
the/DT
perturbed/JJ
molecular/JJ
functional/JJ
modules/NNS
,/,
we/PRP
applied/VBD
the/DT
two/CD
steps/NNS
of/IN
data/NNS
processing/NN
./.
====================
First/RB
,/,
the/DT
log2/NN
transformation/NN
of/IN
fold/JJ
change/NN
between/IN
normal/JJ
and/CC
disease/NN
states/NNS
was/VBD
applied/VBN
for/IN
each/DT
sample/NN
array/NN
./.
====================
Second/RB
,/,
the/DT
average/NN
of/IN
log2-fold/JJ
change/NN
was/VBD
calculated/VBN
for/IN
the/DT
probe/NN
set/NN
of/IN
each/DT
GFC/NN
./.
====================
The/DT
distribution/NN
of/IN
average/JJ
of/IN
log2-fold/JJ
change/NN
for/IN
each/DT
GFC/NN
depending/VBG
on/IN
the/DT
size/NN
of/IN
GFCs/NNS
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
1A/NN
./.
====================
It/PRP
is/VBZ
observed/VBN
that/IN
the/DT
GFCs/NNS
with/IN
relatively/RB
large/JJ
size/NN
tend/NN
to/TO
have/VB
significantly/RB
smaller/JJR
average/NN
values/NNS
of/IN
log2fold/JJ
change/NN
than/IN
the/DT
ones/NNS
with/IN
small/JJ
size/NN
./.
====================
It/PRP
means/NNS
that/DT
it/PRP
is/VBZ
difficult/JJ
to/TO
discriminate/VB
the/DT
perturbed/JJ
molecular/JJ
functional/JJ
modules/NNS
with/IN
relatively/RB
large/JJ
size/NN
using/VBG
the/DT
average/NN
value/NN
of/IN
log2-fold/JJ
change/NN
./.
====================
To/TO
overcome/VB
this/DT
difficulty/NN
,/,
the/DT
average/NN
values/NNS
of/IN
log2-fold/JJ
change/NN
were/VBD
z-transformed/VBN
depending/VBG
on/IN
the/DT
size/NN
of/IN
GFCs/NNS
as/IN
follows/VBZ
./.
====================
First/RB
,/,
the/DT
GFCs/NNS
were/VBD
divided/VBN
into/IN
152/CD
subsets/NNS
,/,
in/IN
which/WDT
each/DT
subset/NN
consists/VBZ
of/IN
GFCs/NNS
with/IN
same/JJ
or/CC
similar/JJ
sizes/NNS
./.
====================
Second/RB
,/,
the/DT
average/NN
value/NN
of/IN
log2fold/JJ
change/NN
in/IN
each/DT
subset/NN
was/VBD
standardized/VBN
such/JJ
that/IN
its/PRP$
mean/NN
and/CC
standard/JJ
deviation/NN
are/VBP
0/CD
and/CC
1/CD
,/,
respectively/RB
./.
====================
After/IN
ztransformation/NN
,/,
it/PRP
is/VBZ
therefore/RB
more/RBR
viable/JJ
to/TO
discriminate/VB
the/DT
perturbed/JJ
GFCs/NNS
of/IN
which/WDT
size/VBP
are/VBP
relatively/RB
large/JJ
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
The/DT
global/JJ
network/NN
of/IN
hierarchical/JJ
molecular/JJ
functional/JJ
classes/NNS
of/IN
GO/NN
was/VBD
constructed/VBN
using/VBG
GFC/NN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
The/DT
“/NN
ztransformed/VBN
”/CD
average/NN
of/IN
log2fold/JJ
change/NN
for/IN
each/DT
GFC/NN
was/VBD
integrated/VBN
with/IN
the/DT
network/NN
to/TO
visualize/VB
the/DT
perturbed/JJ
molecular/JJ
functional/JJ
modules/NNS
in/IN
breast/NN
cancer/NN
tissues/NNS
./.
====================
Note/RB
that/DT
the/DT
colored/JJ
(/(
e./FW
g./FW
,/,
red/JJ
or/CC
blue/JJ
)/)
nodes/NNS
represent/VBP
the/DT
perturbed/JJ
molecular/JJ
functional/JJ
classes/NNS
in/IN
Fig/NN
./.
====================
2/CD
,/,
and/CC
the/DT
subnetwork/NN
with/IN
enriched/JJ
color/JJ
nodes/NNS
could/MD
be/VB
chosen/NN
for/IN
further/JJ
analysis/NN
of/IN
per/FW
turbed/JJ
molecular/JJ
functional/JJ
modules/NNS
./.
====================
As/IN
an/DT
example/NN
,/,
we/PRP
chose/VBP
the/DT
two/CD
sub-networks/NNS
with/IN
relatively/RB
enriched/JJ
perturbed/VBN
GFCs/NNS
in/IN
Fig/NN
./.
====================
2/CD
(/(
A/NN
)/)
and/CC
(/(
B/NN
)/)
for/IN
more/RBR
detailed/JJ
analysis/NN
./.
====================
The/DT
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
in/IN
Fig/NN
./.
====================
2/CD
(/(
A/DT
)/)
and/CC
(/(
B/NN
)/)
are/VBP
listed/VBN
in/IN
Table/JJ
2/CD
and/CC
3/CD
,/,
and/CC
the/DT
differentially/RB
expressed/VBN
genes/NNS
for/IN
those/DT
GFC/NN
in/IN
Table/JJ
1/CD
and/CC
3/CD
are/VBP
listed/VBN
in/IN
Table/JJ
4/CD
and/CC
5/CD
,/,
respectively/RB
./.
====================
Table/JJ
2/CD
includes/VBZ
15/CD
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
that/DT
are/VBP
mainly/RB
encompassed/VBN
by/IN
three/CD
major/JJ
molecular/JJ
functional/JJ
activities/NNS
:/:
1/CD
)/)
G-protein/NN
coupled/VBN
peptide/NN
receptor/NN
activity/NN
,/,
2/CD
)/)
immunoglobulin/NN
binding/VBG
activity/NN
,/,
and/CC
3/CD
)/)
interleukin/NN
binding/VBG
activity/NN
./.
====================
Table/JJ
3/CD
includes/VBZ
38/CD
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
that/DT
are/VBP
mainly/RB
encompassed/VBN
by/IN
peptide/NN
receptor/NN
activity/NN
./.
====================
There/EX
are/VBP
significant/JJ
indications/NNS
that/DT
these/DT
molecular/JJ
functions/NNS
are/VBP
associated/VBN
with/IN
human/JJ
cancers/NNS
as/IN
follows/VBZ
./.
====================
The/DT
G-protein/NN
coupled/VBN
peptide/NN
receptor/NN
activity/NN
encompasses/VBZ
the/DT
perturbed/JJ
molecular/JJ
functional/JJ
modules/NNS
such/JJ
as/IN
C-C/NN
chemokine/NN
binding/receptor/NN
activity/NN
and/CC
C-3X-C/NN
chemokine/NN
binding/receptor/NN
activity/NN
(/(
Table/JJ
2/CD
)/)
including/VBG
differentially/RB
expressed/VBN
genes/NNS
such/JJ
as/IN
CX3CR1/NN
,/,
DARC/NN
,/,
CXCR4/NN
,/,
and/CC
CCRL2/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
Recent/JJ
review/NN
study/NN
by/IN
Dorsam/NN
et/FW
al/JJ
./.
====================
(/(
2007/CD
)/)
addressed/VBD
that/DT
Gprotein-coupled/JJ
receptors/NNS
(/(
GPCRs/NNS
)/)
have/VBP
crucial/JJ
roles/NNS
in/IN
tumor/NN
growth/NN
and/CC
metastasis/NN
and/CC
malignant/JJ
cells/NNS
often/RB
seize/VBP
control/JJ
of/IN
the/DT
normal/JJ
physiological/JJ
functions/NNS
of/IN
GPCRs/NNS
to/TO
survive/VB
,/,
proliferate/VBP
autonomously/RB
,/,
evade/VBP
the/DT
immune/JJ
system/NN
,/,
increase/VBP
their/PRP$
blood/NN
supply/RB
,/,
invade/VBP
their/PRP$
surrounding/VBG
tissues/NNS
and/CC
disseminate/JJ
to/TO
other/JJ
tissues/NNS
./.
====================
Chemokines/NNS
are/VBP
leukocyte/NN
chemoattractants/NNS
that/DT
are/VBP
divided/VBN
structurally/RB
into/IN
four/CD
subgroups/NNS
,/,
based/VBN
on/IN
the/DT
composition/NN
of/IN
cysteine/NN
residues/NNS
in/IN
their/PRP$
aminoterminal/JJ
portion/NN
./.
====================
It/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
target/NN
organs/NNS
for/IN
breast/NN
cancer/NN
metastases/NNS
are/VBP
enriched/VBN
in/IN
the/DT
chemokine/NN
CXCL12/NN
,/,
inducing/VBG
the/DT
specific/JJ
migration/NN
of/IN
breast/NN
tumor/NN
cells/NNS
that/WDT
express/VBP
the/DT
relevant/JJ
receptor/NN
for/IN
this/DT
chemokine/NN
,/,
CXCR4/NN
(/(
Muller/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
The/DT
immunoglobulin/NN
binding/VBG
activity/NN
encompasses/VBZ
the/DT
several/JJ
perturbed/JJ
molecular/JJ
functional/JJ
modules/NNS
such/JJ
as/IN
IgA/E/G/M/NN
receptor/NN
activity/NN
and/CC
polymeric/JJ
immunoglobulin/NN
binding/receptor/NN
activity/NN
(/(
Table/JJ
2/CD
)/)
including/VBG
differentially/RB
expressed/VBN
gene/NN
such/JJ
as/IN
FCGR1B/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
Qiu/NN
et/FW
al/JJ
./.
====================
(/(
2003/CD
)/)
demonstrated/VBD
that/IN
human/JJ
cancers/NNS
of/IN
breast/NN
epithelial/JJ
cancer/NN
lines/NNS
produce/VBP
immunoglobulins/NNS
in/IN
both/CC
cytoplasmic/JJ
and/CC
secreted/VBN
form/NN
./.
====================
Their/PRP$
study/NN
indicates/VBZ
that/IN
prevalent/JJ
expression/NN
of/IN
immuglobulin/NN
in/IN
human/JJ
carcinomas/NNS
and/CC
its/PRP$
growthpromoting/VBG
functions/NNS
may/MD
have/VB
important/JJ
implications/NNS
in/IN
growth/NN
regulation/NN
of/IN
human/JJ
cancers/NNS
./.
====================
Monocyte/NN
activation/NN
in/IN
cancer/NN
patients/NNS
could/MD
be/VB
an/DT
indication/NN
of/IN
anticancer/JJ
activity/NN
./.
====================
However/RB
,/,
Goodale/JJ
et/FW
al/JJ
./.
====================
(/(
2009/CD
)/)
showed/VBD
that/IN
recruitment/NN
of/IN
macrophase/NN
can/MD
promote/VB
tumor/NN
growth/NN
and/CC
angiogenesis/NN
by/IN
analyzing/VBG
the/DT
collected/JJ
peripheral/JJ
blood/NN
using/VBG
flow/NN
cytometry/NN
for/IN
monocyte/NN
activation/NN
./.
====================
They/PRP
demonstrated/VBD
that/IN
metastatic/JJ
breast/NN
cancer/NN
patients/NNS
have/VBP
a/DT
higher/JJR
monocyte/NN
FCGR1B/NN
(/(
CD64/NN
)/)
index/NN
relative/JJ
to/TO
normal/JJ
donors/NNS
and/CC
localized/VBD
breast/NN
cancer/NN
patients/NNS
./.
====================
The/DT
interleukin/NN
binding/VBG
activity/NN
encompasses/VBZ
three/CD
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
such/JJ
as/IN
interleukin6/JJ
binding/VBG
,/,
nerve/NN
growth/NN
factor/NN
binding/VBG
,/,
and/CC
plateletderived/JJ
growth/NN
factor/NN
binding/VBG
(/(
Table/JJ
2/CD
)/)
including/VBG
differentially/RB
expressed/VBN
genes/NNS
such/JJ
as/IN
IL15RA/NN
,/,
IL17RB/NN
,/,
and/CC
PDGFRA/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
Interleukin17/RB
(/(
IL17/NN
)/)
is/VBZ
the/DT
core/NN
member/NN
of/IN
a/DT
group/NN
of/IN
cytokines/NNS
(/(
i./FW
e./FW
,/,
the/DT
IL17/NN
family/NN
)/)
,/,
which/WDT
was/VBD
identified/VBN
as/IN
a/DT
transcript/NN
from/IN
a/DT
rodent/JJ
Tcell/NN
hybridoma/NN
by/IN
Rouvier/NNP
et/FW
al/JJ
./.
====================
(/(
1993/CD
)/)
./.
====================
IL17/NN
induces/VBZ
the/DT
production/NN
of/IN
many/JJ
other/JJ
cytokines/NNS
(/(
e./FW
g./FW
,/,
IL6/NN
,/,
IL1beta/NN
,/,
TGFbeta/NN
,/,
TNFbeta/NN
)/)
,/,
chemokines/NNS
(/(
e./FW
g./FW
,/,
IL8/NN
)/)
and/CC
prostaglandins/NNS
(/(
e./FW
g./FW
,/,
PGE2/NN
)/)
from/IN
many/JJ
cell/NN
types/NNS
(/(
fibroblast/NN
,/,
endothelial/JJ
cells/NNS
,/,
epithelial/JJ
cells/NNS
,/,
keratinocytes/NNS
and/CC
macrophases/NNS
)/)
./.
====================
It/PRP
is/VBZ
well/RB
known/VBN
that/IN
TGF-beta/NN
plays/VBZ
a/DT
role/NN
as/IN
an/DT
antiproliferative/JJ
factor/NN
in/IN
normal/JJ
epithelial/JJ
cells/NNS
and/CC
at/IN
early/JJ
stages/NNS
of/IN
onogenesis/NN
(/(
Hill/JJ
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
The/DT
IL-17/NN
family/NN
has/VBZ
been/VBN
linked/VBN
to/TO
many/JJ
immune/autoimmune/JJ
related/JJ
diseases/NNS
including/VBG
anti-tumor/JJ
immunity/NN
(/(
Aggarwal/NN
and/CC
Gurney/NNP
,/,
2002/CD
)/)
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
this/DT
study/NN
suggests/VBZ
molecular/JJ
functional/JJ
modules/NNS
for/IN
breast/NN
cancer/NN
are/VBP
down-regulated/VBN
in/IN
Table/JJ
2/CD
./.
====================
The/DT
plateletderived/JJ
growth/NN
factors/NNS
(/(
PDGFAA/NN
and/CC
B/NN
)/)
are/VBP
important/JJ
factors/NNS
regulating/VBG
cell/NN
proliferation/NN
,/,
cellular/JJ
differentiation/NN
,/,
cell/NN
growth/NN
,/,
development/NN
and/CC
many/JJ
diseases/NNS
including/VBG
cancer/NN
./.
====================
PDGF/NN
and/CC
its/PRP$
receptor/NN
are/VBP
important/JJ
targets/NNS
in/IN
cancer/NN
therapy/NN
based/VBN
on/IN
angiogenesis/NN
(/(
Sennino/NN
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
The/DT
peptide/NN
receptor/NN
activity/NN
encompasses/VBZ
38/CD
perturbed/VBN
molecular/JJ
functional/JJ
modules/NNS
(/(
Table/JJ
3/CD
)/)
including/VBG
several/JJ
differentially/RB
expressed/VBN
genes/NNS
(/(
Table/JJ
5/CD
)/)
./.
====================
There/EX
are/VBP
significant/JJ
amount/NN
of/IN
in/FW
vitro/FW
observation/NN
that/IN
peptide/NN
receptors/NNS
are/VBP
expressed/VBN
in/IN
large/JJ
quantities/NNS
in/IN
certain/JJ
tumors/NNS
./.
====================
Reubi/NN
(/(
2003/CD
)/)
summarized/VBD
and/CC
critically/RB
evaluated/VBD
the/DT
in/FW
vitro/FW
data/NNS
on/IN
peptide/NN
and/CC
peptide/NN
receptor/NN
expression/NN
in/IN
human/JJ
cancers/NNS
,/,
which/WDT
could/MD
be/VB
considered/VBN
to/TO
be/VB
the/DT
molecular/JJ
basis/NN
for/IN
peptide/NN
receptor/NN
targeting/VBG
of/IN
tumors/NNS
./.
====================
Moreover/RB
,/,
there/RB
are/IN
considerable/JJ
amount/IN
of/IN
genes/RB
in/IN
Table/JJ
5/RB
that/IN
are/IN
implicated/RB
to/IN
play/CC
roles/RB
in/IN
the/DT
progression/RB
of/IN
breast/RB
cancer/RB
or/CC
other/JJ
cancers/RB
,/,
including/VBG
BDKRB2/RB
(/(
Greco/NNP
et/FW
al./FW
,/,
2005/RB
)/)
,/,
PLCB1/NNP
(/(
Naor/CC
,/,
2009/RB
)/)
,/,
PLD1/NNP
(/(
Eisen/NNP
and/CC
Brown/RB
,/,
2002/RB
)/)
,/,
GPLD1/NNP
(/(
Derevianko/RB
et/FW
al./FW
,/,
1996/RB
;/IN
Williams/RB
et/FW
al./FW
,/,
2001/RB
)/)
,/,
EXO1/NNP
(/(
Naderi/NNP
et/FW
al./FW
,/,
2007/RB
)/)
,/,
ANG/RB
(/(
Campo/NNP
et/FW
al./FW
,/,
2005/RB
)/)
,/,
ISG20/HEM45/RB
(/(
Pentecost/RB
,/,
1998/RB
)/)
,/,
AZGP1/ZAG/RB
(/(
Hassan/NNP
et/FW
al./FW
,/,
2009/RB
)/)
,/,
ZKSCAN1/NNP
(/(
Pennanen/NNP
et/FW
al./FW
,/,
2009/RB
)/)
,/,
REXO2/RB
(/(
Flanagan/NNP
et/FW
al./FW
,/,
2009/RB
)/)
,/,
CTDSPL/NNP
(/(
Murabito/RB
et/FW
al./FW
,/,
2007/RB
)/)
,/,
NT5E/RB
(/(
Zhou/NNP
et/FW
al./FW
,/,
2007/RB
)/)
,/,
DLG1/RB
(/(
Fuja/RB
et/FW
al./FW
,/,
2004/RB
)/)
,/,
PPM1A/RB
(/(
Lin/RB
et/FW
al./FW
,/,
2006/RB
)/)
,/,
TIAM1/NNP
(/(
Lane/NNP
et/FW
al./FW
,/,
2008/RB
)/)
,/,
BAG4/RB
(/(
Yang/NNP
et/FW
al./FW
,/,
2006/RB
)/)
,/,
BRAF/RB
(/(
Hollestelle/RB
,/,
et/FW
al./FW
,/,
2007/RB
)/)
,/,
CLDN4/NNP
(/(
Kulka/NNP
et/FW
al./FW
,/,
2009/RB
)/)
,/,
F3/TF/RB
(/(
Amirkhosravi/NNP
et/FW
al./FW
,/,
1998/RB
)/)
,/,
FZD1/RB
(/(
Benhaj/NNP
et/FW
al./FW
,/,
2006/RB
)/)
,/,
NGFR/RB
(/(
Reis-Filho/NNP
et/FW
al./FW
,/,
2006/RB
)/)
,/,
LEFR/NNP
(/(
Han/NNP
et/FW
al./FW
,/,
2008/RB
)/)
,/,
RAC1/NNP
(/(
Han/NNP
et/FW
al./FW
,/,
2008/RB
)/)
,/,
PLXNB1/NNP
(/(
Rody/NNP
et/FW
al./FW
,/,
2007/RB
)/)
,/,
IGHG1/RB
(/(
Kabbage/RB
et/FW
al./FW
,/,
2008/RB
)/)
,/,
IGHG3/RB
(/(
Bin/NNP
Amer/RB
et/FW
al./FW
,/,
2008/RB
)/)
,/,
TLR3/RB
(/(
Salaun/NNP
et/FW
al./FW
,/,
2006/RB
)/)
,/,
FBN1/RB
(/(
Chen/NNP
et/FW
al./FW
,/,
2007/RB
)/)
,/,
DUSP4/RB
(/(
Venter/RB
et/FW
al./FW
,/,
2005/RB
)/)
,/,
PTPN3/NNP
(/(
Wang/NNP
et/FW
al./FW
,/,
2004/RB
)/)
,/,
CDKN3/KAP/NNP
(/(
Lee/NNP
et/FW
al./FW
,/,
2000/RB
)/)
,/,
and/CC
etc/IN
./.
====================
Based/VBN
on/IN
the/DT
integration/NN
of/IN
GFC/NN
codes/VBZ
and/CC
microarray/NN
data/NNS
of/IN
breast/NN
cancer/NN
tissues/NNS
,/,
we/PRP
present/VBP
several/JJ
perturbed/JJ
molecular/JJ
functions/NNS
,/,
which/WDT
are/VBP
implicated/VBN
in/IN
the/DT
progression/NN
of/IN
breast/NN
cancer/NN
./.
====================
It/PRP
was/VBD
also/RB
found/VBD
that/IN
these/DT
selected/VBN
molecular/JJ
functions/NNS
include/VBP
several/JJ
known/JJ
breast/NN
cancer/NN
related/JJ
genes/NNS
./.
====================
Moreover/RB
,/,
it/PRP
is/VBZ
believed/VBN
that/IN
our/PRP$
strategy/NN
provides/VBZ
efficient/JJ
visual/JJ
interpretability/NN
of/IN
microarray/NN
data/NNS
integrated/VBD
with/IN
GFC/NN
to/TO
understand/VB
the/DT
perturbed/JJ
molecular/JJ
functions/NNS
in/IN
complex/NN
progressive/JJ
diseases/NNS
such/JJ
as/IN
breast/NN
cancer/NN
./.
====================
Therefore/RB
,/,
the/DT
selected/VBN
perturbed/VBN
molecular/JJ
functions/NNS
in/IN
this/DT
study/NN
could/MD
be/VB
further/RBR
investigated/VBD
to/TO
understand/VB
the/DT
basic/JJ
molecular/JJ
functions/NNS
,/,
which/WDT
discriminate/VBP
different/JJ
breast/NN
cancer/NN
types/NNS
./.
====================
